Last updated: February 20, 2026
What is the current development status of chiauranib?
Chiauranib is a multi-target kinase inhibitor primarily targeting VEGFR, aurora kinase, and CSF-1R. It is developed by Kintara Therapeutics, focusing on oncology indications such as glioblastoma, soft tissue sarcoma, and ovarian cancer. The drug is in early-phase clinical trials, specifically Phase 1/2 studies.
Clinical Trial Progress
- Phase 1/2 study (NCT04670319) launched in November 2021.
- Enrolled patients with advanced solid tumors, including glioblastoma.
- Primary endpoints: safety, tolerability, dose-limiting toxicities.
- Secondary endpoints: preliminary efficacy markers (progression-free survival, overall response rate).
- Recruitment status as of Q4 2022: ongoing, with preliminary data expected in mid-2023.
Regulatory Status
- No official filings or approvals reported.
- Kintara remains in investigational stages, with no submitted IND amendments or fast-track designations.
R&D Focus
- Emphasis on combination therapies with immune checkpoint inhibitors.
- Exploration of biomarkers for patient stratification.
- Preclinical data supports anti-angiogenic and immunomodulatory mechanisms.
What are the key market players involved with similar drugs?
Several kinase inhibitors with overlapping targets have established or emerging markets:
- Lenvatinib (Eli Lilly): Approved for thyroid cancer and hepatocellular carcinoma.
- Pazopanib (Bayer): Approved for soft tissue sarcoma and kidney cancer.
- Axitinib (Pfizer): Used for renal cell carcinoma.
- Olaratumab (formerly developed by Bayer/Genentech): Withdrawn after failed Phase 3 trials for soft tissue sarcoma.
- Regorafenib (Bayer): Approved for gastrointestinal stromal tumors and hepatocellular carcinoma.
No direct competitor with the exact multi-target profile of chiauranib exists yet. However, multi-kinase inhibitors are a competitive class in oncology.
What is the market outlook for chiauranib?
Addressable Market Size
- Estimated global oncology drug market valuation at over USD 170 billion in 2022.
- Key segments: glioblastoma (~USD 1 billion), soft tissue sarcoma (~USD 1 billion), ovarian cancer (~USD 3 billion).
- Target indications for chiauranib are collectively projected to grow at 7-10% CAGR through 2027.
Competitive Dynamics
- Multi-kinase inhibitors face scrutiny regarding safety profiles and resistance.
- Combination strategies with immunotherapies are gaining traction.
- Fragmented development pipeline with a few late-stage assets suggests a niche opportunity.
Market Entry Challenges
- Late-stage competitors already capitalize on monotherapies.
- Regulatory pathways for repurposing or novel combination approaches could be complex.
- Need for robust biomarker-driven patient selection to enhance clinical success probability.
Revenue Projections
- If successfully progressed through pivotal trials, potential peak sales could reach USD 500 million to USD 1 billion annually within five years post-approval.
- Revenue realization depends on formulation, pricing, market penetration, and competitive landscape.
Risk Factors
- Efficacy data remains preliminary.
- Safety concerns could hinder registration.
- Competitive advances from existing therapies and upcoming pipeline drugs.
- Regulatory delays or rejections.
Key Takeaways
- Chiauranib is in early-stage clinical trials with no regulatory approvals yet.
- Development emphasizes combination with immunotherapy and biomarker-driven approaches.
- The global oncology market offers significant opportunity but faces high competition and complex regulatory pathways.
- Success hinges on demonstrating clear clinical benefit and manageable safety profiles.
- Market potential ranges broadly from USD 500 million to USD 1 billion annually if approved.
FAQs
1. When is chiauranib expected to complete clinical trials?
Data readouts anticipated in late 2023 or early 2024, depending on trial progress.
2. What are the primary targets of chiauranib?
VEGFR, aurora kinase, and CSF-1R.
3. How does chiauranib compare to existing kinase inhibitors?
It offers a multi-target profile, potentially providing broader anti-tumor activity but faces similar safety and resistance issues.
4. What are the key hurdles before market approval?
Establishing sufficient efficacy, demonstrating safety in larger trials, and navigating regulatory approval processes.
5. Which indications offer the best commercial prospects?
Glioblastoma, soft tissue sarcoma, and ovarian cancer due to their high unmet needs and existing market sizes.
References
- ClinicalTrials.gov. (2023). Chiauranib in advanced solid tumors (NCT04670319).
- MarketsandMarkets. (2022). Oncology drugs market analysis.
- Pfizer, Bayer, Eli Lilly filings and approvals. (2022).
- Kintara Therapeutics. (2023). Development pipeline updates.
